- Trial phase
- Approved
- Time to market
- Already on the market since 2013.
- Why 4/10
- Kadcyla is already approved and marketed. No new PDUFA or pivotal Phase 3 readout is scheduled in the next 12 months. For Roche (RHHBY), Kadcyla is one of many products in a large, diversified portfolio, so even a significant label change or competitive shift would not drive a binary share-price move.
The VIVS filing hint is a dead end, VivoSim Labs does not develop trastuzumab emtansine. Investors focused on this drug should watch Roche (RHHBY) for Kadcyla sales trends and competition from Enhertu (AZN/Daiichi), not VIVS. There is no near-term binary catalyst for Kadcyla.
Price Chart
Executive Summary
Trastuzumab emtansine (brand name Kadcyla) is an already-approved antibody-drug conjugate (ADC) developed by Genentech (Roche, traded OTC as RHHBY). Originally FDA-approved in February 2013 for HER2-positive metastatic breast cancer, it received a supplemental FDA approval in May 2025. The filing hint pointing to VivoSim Labs (VIVS) is misleading, VIVS is a separate micro-cap biotech with a drug-toxicity testing platform that only mentioned the drug in a benchmark comparison press release; it does not develop or own Kadcyla. For Roche, Kadcyla is one of many marketed products, faces growing competition from second-generation ADCs like Enhertu, and has no imminent binary regulatory catalyst.
How It Works
Kadcyla is an antibody-drug conjugate (ADC), think of it as a targeted missile. The antibody part (trastuzumab) latches onto HER2 proteins that are overexpressed on certain cancer cells, then the attached chemotherapy payload (emtansine/DM1) is released directly inside the cancer cell to kill it.
Trial Status
Kadcyla was originally FDA-approved in February 2013 for HER2-positive metastatic breast cancer. It received a supplemental FDA approval in May 2025. Completed and ongoing Phase 2 trials are exploring its use in additional HER2-amplified solid tumor types. A safety labeling update was made in April 2026 adding boxed warnings for hepatotoxicity, cardiac toxicity, and embryo-fetal toxicity.
The Two-Sided Case
Upcoming Catalysts
- Kadcyla commercial sales performance in Roche's quarterly earnings reports
- Potential new trial readouts in additional HER2-amplified tumor types
- Competitive dynamics versus Enhertu (trastuzumab deruxtecan) in the HER2-positive breast cancer market
Source Filing
The SecBot filing or press-release report that triggered this drug report:
VivoSim Labs, Inc. Press Release VIVS ·Originating report